Department of Neuropsychopharmacology
Karl Broich has not added Biography.
If you are Karl Broich and would like to personalize this page please email our Author Liaison for assistance.
Placebo-controlled studies in depression: necessary, ethical and feasible.
European archives of psychiatry and clinical neuroscience Feb, 2003 | Pubmed ID: 12664309
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach.
Psychiatry research Aug, 2005 | Pubmed ID: 16043331
Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.
European archives of psychiatry and clinical neuroscience Feb, 2006 | Pubmed ID: 16078087
Regulatory issues in vascular dementia: a European perspective.
International psychogeriatrics / IPA , 2003 | Pubmed ID: 16191258
Mild cognitive impairment.
Lancet (London, England) Apr, 2006 | Pubmed ID: 16631882
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Thrombosis and haemostasis Oct, 2006 | Pubmed ID: 17003918
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Journal of psychopharmacology (Oxford, England) Nov, 2006 | Pubmed ID: 17060346
Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
International psychogeriatrics / IPA Jun, 2007 | Pubmed ID: 17433121
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology May, 2009 | Pubmed ID: 19269795
Biological markers for early detection and pharmacological treatment of Alzheimer's disease.
Dialogues in clinical neuroscience , 2009 | Pubmed ID: 19585950
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.
Journal of neurology, neurosurgery, and psychiatry Feb, 2010 | Pubmed ID: 19770163
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.
European archives of psychiatry and clinical neuroscience Feb, 2010 | Pubmed ID: 19888620
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
Nature reviews. Drug discovery Jul, 2010 | Pubmed ID: 20592748
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.
The Journal of clinical psychiatry Aug, 2010 | Pubmed ID: 20673551
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.
The Journal of clinical psychiatry Aug, 2010 | Pubmed ID: 20797373
Anticholinergic drug use and risk for dementia: target for dementia prevention.
European archives of psychiatry and clinical neuroscience Nov, 2010 | Pubmed ID: 20960005
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.
Journal of neural transmission (Vienna, Austria : 1996) Jan, 2012 | Pubmed ID: 21755462
Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
Progress in neurobiology Dec, 2011 | Pubmed ID: 21945642
Burnout: a fashionable diagnosis.
Deutsches Ärzteblatt international Nov, 2011 | Pubmed ID: 22163259
Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis.
Advances in experimental medicine and biology , 2012 | Pubmed ID: 22453990
DSM-5 and clinical trials in psychiatry: challenges to come?
Nature reviews. Drug discovery Aug, 2012 | Pubmed ID: 22850770
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen , 2013 | Pubmed ID: 23663906
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimer's & dementia : the journal of the Alzheimer's Association Jul, 2013 | Pubmed ID: 23809364
[Personalised medicine].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz Nov, 2013 | Pubmed ID: 24170074
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
Biochemical pharmacology Apr, 2014 | Pubmed ID: 24275164
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Alzheimer's & dementia : the journal of the Alzheimer's Association Oct, 2014 | Pubmed ID: 24418060
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association Apr, 2015 | Pubmed ID: 24751826
The CaV2.3 R-type voltage-gated Ca2+ channel in mouse sleep architecture.
Sleep May, 2014 | Pubmed ID: 24790266
Addressing the regulatory and scientific challenges in multiple sclerosis--a statement from the EU regulators.
Multiple sclerosis (Houndmills, Basingstoke, England) Sep, 2014 | Pubmed ID: 25160121
Risk of dementia in elderly patients with the use of proton pump inhibitors.
European archives of psychiatry and clinical neuroscience Aug, 2015 | Pubmed ID: 25341874
[Safety of medical devices].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz Dec, 2014 | Pubmed ID: 25394355
Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
Expert review of neurotherapeutics Jan, 2015 | Pubmed ID: 25537424
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.
Nature reviews. Drug discovery Apr, 2015 | Pubmed ID: 25829266
Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease.
Neural plasticity , 2015 | Pubmed ID: 25883808
Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.
Neural plasticity , 2015 | Pubmed ID: 25922768
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
Journal of Alzheimer's disease : JAD Sep, 2015 | Pubmed ID: 26402088
Identification and validation of biomarkers for autism spectrum disorders.
Nature reviews. Drug discovery Jan, 2016 | Pubmed ID: 26718285
EEG Radiotelemetry in Small Laboratory Rodents: A Powerful State-of-the Art Approach in Neuropsychiatric, Neurodegenerative, and Epilepsy Research.
Neural plasticity , 2016 | Pubmed ID: 26819775
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
JAMA neurology Apr, 2016 | Pubmed ID: 26882076
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Alzheimer's & dementia : the journal of the Alzheimer's Association Mar, 2016 | Pubmed ID: 27012484
Drug Regulation and Pricing--Can Regulators Influence Affordability?
The New England journal of medicine May, 2016 | Pubmed ID: 27168431
Sampling rate, signal bandwidth and related pitfalls in EEG analysis.
Journal of neuroscience methods Aug, 2016 | Pubmed ID: 27172844
The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
Multiple sclerosis (Houndmills, Basingstoke, England) Aug, 2016 | Pubmed ID: 27465615
Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data.
Journal of Alzheimer's disease : JAD Sep, 2016 | Pubmed ID: 27567804
The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
Biomarkers in medicine Dec, 2016 | Pubmed ID: 27661101
[Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz Dec, 2016 | Pubmed ID: 27778087
Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease.
Neural plasticity , 2016 | Pubmed ID: 27840743
Review: Cav2.3 R-type Voltage-Gated Ca(2+) Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity.
The open neurology journal , 2016 | Pubmed ID: 27843503
Motor Cortex Theta and Gamma Architecture in Young Adult APPswePS1dE9 Alzheimer Mice.
PloS one , 2017 | Pubmed ID: 28072877
Andreas Lundt1,2,
Julien Soos1,
Christina Henseler1,
Muhammad Imran Arshaad1,
Ralf Müller3,
Dan Ehninger4,
Jürgen Hescheler5,
Agapios Sachinidis5,
Karl Broich6,
Carola Wormuth1,7,
Anna Papazoglou1,
Marco Weiergräber1
1Experimental Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices,
2, KBRwyle GmbH,
3Cognitive Neurophysiology, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne,
4Molecular and Cellular Cognition, German Center for Neurodegenerative Diseases (DZNE),
5Institute of Neurophysiology, Faculty of Medicine, University of Cologne,
6, Federal Institute for Drugs and Medical Devices (BfArM),
7, Thescon GmbH
ÜBER JoVE
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten